JNJ Johnson & Johnson
Mature pharma trading at premium; fair value well below current price.
The story
JNJ is a mature pharma and medtech conglomerate navigating post-Kenvue spin-off life as a pure-play health company. Its diversified portfolio and scale provide moderate moat, but patent cliffs (Stelara) and competitive pressure limit growth to low single digits. The company is in late maturity with limited excess return runway.
Revenue growth starts at 5% reflecting Stelara biosimilar headwinds offset by new pipeline launches, fading to 3% terminal near GDP-like rates. Target margin of 25% normalizes below the 35.6% TTM peak (which was inflated by one-offs and Kenvue separation effects) toward sustainable pharma conglomerate economics. Sales-to-capital of 1.20 reflects JNJ's asset-heavy manufacturing and R&D base, improving modestly from the 0.76 TMM as Kenvue separation complexities fade but remaining below industry leaders given scale constraints.
Value drivers
| Revenue growth (Y1) | 5.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 7y |
| Target operating margin | 25.0% |
| Years to target margin | 5 |
| Sales-to-capital | 1.20 |
| Beta | 0.95 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 8.9% |
| Terminal WACC | 9.2% |
Valuation bridge
| PV of explicit FCFF | 102.92B |
| PV of terminal value | 195.21B |
| Equity value | 264.51B |
| ÷ shares → per share | $109.76 |
News
neutral -0.10 · 8 articles
- Merck Stock Vs. LLY: Why Is The Slower Grower More Expensive?
- Barron’s Got Cooper Wrong but the Contact-Lens Stock Now Looks Cheap
- JNJ Stock: Is the Rally Running Out of Steam?
- The Portfolio You Need to Generate $500 a Month in Dividend Income
- Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
- AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next
- Why Has AbbVie Gone Quiet About Humira?
- 2 Reasons Cooper Companies Stock Is By Far the Worst in the S&P 500 Today
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 102.83B | 5.0% | 26.4% | 22.34B | 4.08B | 18.26B | 16.76B |
| 2 | 107.62B | 4.7% | 26.1% | 23.07B | 4.00B | 19.07B | 16.07B |
| 3 | 112.29B | 4.3% | 25.7% | 23.75B | 3.89B | 19.86B | 15.36B |
| 4 | 116.78B | 4.0% | 25.4% | 24.36B | 3.74B | 20.61B | 14.63B |
| 5 | 121.06B | 3.7% | 25.0% | 24.90B | 3.57B | 21.33B | 13.90B |
| 6 | 125.10B | 3.3% | 25.0% | 25.73B | 3.36B | 22.37B | 13.38B |
| 7 | 128.85B | 3.0% | 25.0% | 26.50B | 3.13B | 23.37B | 12.83B |
Key risks
- Stelara biosimilar erosion faster than pipeline can replace
- Talc litigation overhang and ongoing legal costs
- Pipeline disappointments in oncology and immunology
Catalysts
- Successful launch of Stelara successor (Tremfya expansion) and oncology pipeline
- Medtech segment recovery post-procedure backlog normalization
- Margin expansion as post-spin restructuring completes